First Manhattan CO Opti Nose, Inc. Transaction History

First Manhattan CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.68 - $3.7 $1,680 - $3,700	-1,000 Reduced 66.67%	500 $0
Q3 2022 Nov 14, 2022	SELL	$3.43 - $4.01 $3,430 - $4,010	-1,000 Reduced 40.0%	1,500 $5,000
Q2 2021 Aug 16, 2021	BUY	$2.91 - $3.83 $6,111 - $8,043	2,100 Added 525.0%	2,500 $7,000
Q1 2021 May 14, 2021	SELL	$3.47 - $4.75 $3,817 - $5,225	-1,100 Reduced 73.33%	400 $1,000
Q4 2020 Feb 16, 2021	BUY	$3.2 - $4.98 $4,800 - $7,470	1,500 New	1,500 $6,000

88.3M

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $42.5M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.